Q2 EPS Estimate for PTC Therapeutics Decreased by Analyst

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - William Blair dropped their Q2 2025 earnings estimates for PTC Therapeutics in a report released on Tuesday, June 3rd. William Blair analyst S. Corwin now expects that the biopharmaceutical company will earn ($1.23) per share for the quarter, down from their previous estimate of ($1.00). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at $6.38 EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.36 EPS, Q4 2026 earnings at $0.77 EPS and FY2026 earnings at $0.77 EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating the consensus estimate of $0.85 by $9.19. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. The business's revenue was down 9.6% on a year-over-year basis. During the same period last year, the company posted ($1.20) earnings per share.

PTCT has been the topic of several other research reports. Bank of America upgraded shares of PTC Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $55.00 to $68.00 in a research report on Friday, May 9th. Citigroup upgraded shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and reduced their price target for the company from $50.00 to $40.00 in a research report on Wednesday, May 7th. Wall Street Zen cut shares of PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. Scotiabank started coverage on shares of PTC Therapeutics in a research report on Friday, March 7th. They set a "sector perform" rating and a $55.00 price target on the stock. Finally, Barclays reduced their price target on shares of PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.75.

PTC Therapeutics Stock Up 0.8%

Shares of NASDAQ:PTCT traded up $0.40 during midday trading on Friday, hitting $52.13. 936,061 shares of the stock traded hands, compared to its average volume of 868,406. PTC Therapeutics has a one year low of $28.72 and a one year high of $58.38. The business's 50 day moving average is $46.33 and its two-hundred day moving average is $47.83. The stock has a market capitalization of $4.13 billion, a PE ratio of -8.78 and a beta of 0.51.

Insiders Place Their Bets

In other news, VP Mark Elliott Boulding sold 883 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the sale, the vice president now owns 103,901 shares in the company, valued at $4,781,524.02. This represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Lee Scott Golden sold 897 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total transaction of $42,114.15. Following the sale, the executive vice president now owns 75,997 shares in the company, valued at approximately $3,568,059.15. The trade was a 1.17% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,034 shares of company stock worth $1,405,767. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of PTC Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company's stock valued at $414,332,000 after buying an additional 53,688 shares during the last quarter. Wellington Management Group LLP lifted its position in PTC Therapeutics by 13.2% during the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock valued at $276,161,000 after purchasing an additional 632,049 shares during the period. Toronto Dominion Bank bought a new position in PTC Therapeutics during the fourth quarter valued at approximately $148,363,000. Janus Henderson Group PLC lifted its position in PTC Therapeutics by 24.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company's stock valued at $105,015,000 after purchasing an additional 455,698 shares during the period. Finally, Driehaus Capital Management LLC lifted its position in PTC Therapeutics by 45.3% during the first quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock valued at $77,084,000 after purchasing an additional 471,586 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.